Literature DB >> 870175

Relative biochemical aspects of low and high doses of methotrexate in mice.

D S Zaharko, W P Fung, K H Yang.   

Abstract

During low infusion rates of methotrexate (1.0 microng/hr/mouse; plateau plasma concentration, 2 X 10(-8) M), [3H]deoxyuridine incorporation into DNA was inhibited to a significant degree in small intestine and femur marrows. However, incorporation of [3H]thymidine into intestinal DNA was stimulated at this low infusion rate. During high infusion rates of methotrexate (10 microng/hr/mouse, plateau plasma concentration, 4 X 10(-7) M), inhibition of the incorporation of [3H]deoxyuridine at the steady state levels of plasma methotrexate in both the small intestine and femur marrow was significant. In contrast to stimulation at the low infusion rate, incorporation of [3H]thymidine into intestinal DNA at this high infusion rate was inhibited to a significant degree. Inhibition was not statistically significant in femur marrow DNA. The inhibition of [3H]thymidine into intestinal DNA could be reversed by the simultaneous infusion of inosine. Thus, in the in vivo system, an antipurine effect on DNA Synthesis at high methotrexate plasma concentration in the small intestine was observed. This antipurine effect was not apparent at the lower concentrations. The lower concentration, however, could still inhibit [3H]deoxyuridine incorporation into intestinal and femur marrow DNA to a significant enough degree that, if prolonged, it would resultin lethality to the mice. The thymineless state can be maintained for at most 60 hr in mice without lethal toxicity, whereas the antipurine state can be maintained for no longer than 18 hr in mice without some lethal toxicity. These data have important implications in rescue studies using thymidine or leucovorin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870175

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors:  W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 2.  Cancer chemotherapy: new strategies for success.

Authors:  N A Berger
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

Review 3.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 4.  Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity.

Authors:  Nikki de Rouw; Berber Piet; Hieronymus J Derijks; Michel M van den Heuvel; Rob Ter Heine
Journal:  Drug Saf       Date:  2021-11-06       Impact factor: 5.606

5.  Comparison of cytostatic sensitivities of L 1210 cells and human stimulated lymphocytes in three cell proliferation assays.

Authors:  F Ali-Osman; H R Maurer
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

6.  Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.

Authors:  M Jonnalagadda; C E Brown; W C Chang; J R Ostberg; S J Forman; M C Jensen
Journal:  Gene Ther       Date:  2013-01-10       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.